Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer

Overview of attention for article published in Einstein (São Paulo), January 2017

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (53rd percentile)

Mentioned by

policy: 1 policy source

Citations

dimensions_citation: 11 Dimensions

Readers on

mendeley: 39 Mendeley

Summary Policy documents Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Enzalutamide for treating hormone-sensitive metastatic prostate cancer : Committee papers

Cited by National Institute for Health and Care Excellence on 07 Jul 2021

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.